

Is Better Patient Selection the Key to Successful HIFU Therapy for Prostate Cancer “Sweet Spot Study”

Preliminary Results of an Optimization Study Designed to Find the Therapeutic “Sweet Spot”

Ronald Wheeler, Stephen Leslie Gerald Grubbs, Brian Wheeler, Herman Fernandez, Aleah Bond
Creighton University (Dr. Leslie & Aleah Bond) & The Diagnostic Center for Disease (Dr. Wheeler & team)

Authors	Number of Patients	Age	Gleason Score	Pre-RX PSA	Post-RX PSA Nadir	Stage	Follow-up (mo.)	MP-MRI	BDFR	Re-RX Rate Salvage.
Wheeler, R. Leslie, S. ‘Sweet Spot Study’ (Unique research using HIFU Technology)	67	61.5 Range: (49-81)	6=36 7(3+4)=22 7(4+3)=6 8=2 9=1	5.2	0.137 ng/ml (mean) (89% nadir ≤ 0.30 ng/ml); Range: 0-.46	T1-T2 N0,M0	85 mo. (Mean: 27.3 mo.) Range: 3-85	Pre-Op (All patients); Scans Post-op also	99% @ 7(+yrs) (Phoenix Definition)	1 (EBT)
Orovan,W. etal Cleveland Clinic British Journal of Urology- 2012 Ablatherm HIFU Only	402	62.7 (±7.5)	6=183 7(3+4)=130 7(4+3)=63	6.6 ±7.5	0.38 (0.7) ng/ml nadir Low Risk; 0.35(0.68) ng/ml nadir Intermediate. Risk	T1-T2 N0,M0	48 mo. (Mean-24mo.) Range: 6-48	No Scans; Biopsies: 50/78 pts.with PSA nadir >0.5 p/o	72% @ 4yrs (Horowitz) GS 6 -76% GS 7 – 69.5%	12 (HIFU) 6 (RRP) 4 (EBT) 4 (ADT) 7 (AS)

Research Author(s)	Country	BDF Rates - Minimum of 34 months (mean); Minimum 67 patients
Blana, A. et al using Ablatherm FR	Germany (2008)	77% Low and Intermediate Grades at 5 years 69% Low and Intermediate Grades at 7 years
Blana, A., Chaussy, C. et al using Ablatherm FR	Germany (2009)	75% Low and Intermediate Grades
Uchida, T., Shoji, S., Nakono, M., et al. Using Sonablate technology (USA) only	Japan (2008)	84% - Low Grade 64% Intermediate Grade
Crouzet, S. et al. using Ablatherm FR	France (2010)	83% - Low Grade 75% - Intermediate Grade
Agarwala, P., Sadetsky, N., Konety, B. et al.	CaPSURE Data (2008)	37% - All treatment Grades – EBRT 70% - All treatment Stages -Surgical

Take Home Messages:

- Number One in Patient Outcome Data (► 90% cured in almost 500 patients) - Using HIFU @ Greater than 10 years!
- Number One in Fewest Patients treated Twice with HIFU (Our Niche Market is curing Aggressive Prostate Cancers; GS: 7, 8, 9, 10)
- Number One in the World’s Market place with fewest side effects! Expect Potency & Continence as well as an absence of fistulas
- CaPSURE data demonstrates the need for diagnostic help with 3.T MP-MRI scanning and improved techniques using Ablatherm HIFU!
- Don’t accept a 70% success rate with radical prostatectomy and a 63% recurrence rate following radiation treatment (CaPSURE DATA)
- To Learn more: Contact us for a Free Consultation at: 1-877-766-8400 or Visit our Website: www.HIFUcoa.com